Targeting Oncomucin-Driven Immunosuppression Improves the Efficacy of K-ras(G12D) Inhibition in Pancreatic Cancer.

Targeting oncomucin-driven immune suppression enhances K-ras(G12D) inhibitor effectiveness in pancreatic cancer, reducing tumor burden and immune checkpoints.

• Why it matters: Pancreatic ductal adenocarcinoma (PDA) exhibits immune evasion facilitated by oncoMUCs, yet their collective role in tumor progression and immune suppression remains poorly understood, limiting therapeutic options.
• What they did: Researchers integrated single-cell RNA sequencing, immunostaining, and murine models to analyze oncoMUCs (MUC4, MUC16, MUC5AC) and their impact on immune checkpoints and signaling pathways, testing pharmacologic targeting combined with K-ras G12D inhibition.
• The result: Inhibiting oncoMUCs decreased immune checkpoint expression, increased immune cell infiltration, and improved response to K-ras G12D inhibition, highlighting oncoMUCs as promising immune regulators and therapeutic targets in PDA.